ScholarIQanswers from OpenAlex & ORCID
Kazuo Fujihara
ResearcherPublications, citations & collaboration network
Kazuo Fujihara is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kazuo Fujihara have?
ScholarIQindexed works
Kazuo Fujihara has 432 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kazuo Fujihara have?
ScholarIQcitation count
Kazuo Fujihara has 50,997 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kazuo Fujihara?
ScholarIQh-index
Kazuo Fujihara has an h-index of 80 in OpenAlex.
What is the i10-index of Kazuo Fujihara?
ScholarIQi10-index
Kazuo Fujihara has an i10-index of 257 in OpenAlex.
What is the ORCID of Kazuo Fujihara?
ScholarIQorcid
The ORCID for Kazuo Fujihara is on the source record.
What is the OpenAlex record for Kazuo Fujihara?
ScholarIQopenalex
The OpenAlex for Kazuo Fujihara is on the source record.
What are the most-cited papers on Kazuo Fujihara?
ScholarIQmost cited works
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William M. Carroll, Tanuja Chitnis, de Sèze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Aurélio Lana–Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony Traboulsee, Patrick Waters, Kay E. Wellik, Brian G. Weinshenker
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
Brenda Banwell, Jeffrey L. Bennett, Romain Marignier, Ho Jin Kim, Fabienne Brilot, Eoin P. Flanagan, Sudarshini Ramanathan, Patrick Waters, Sílvia Tenembaum, Jennifer Graves, Tanuja Chitnis, Alexander U. Brandt, Cheryl Hemingway, Rinze F. Neuteboom, Lekha Pandit, Markus Reindl, Albert Saiz, Douglas Kazutoshi Sato, Kevin Rostásy, Friedemann Paul, Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Douglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurélio Lana–Peixoto, Patrick Waters, Frederico Mennucci de Haidar Jorge, Toshiyuki Takahashi, Ichiro Nakashima, Samira Luísa Apóstolos‐Pereira, Natália Cirino Talim, Renata Simm, Angelina Maria Martins Lino, Tatsuro Misu, Maria Isabel Leite, Masashi Aoki, Kazuo Fujihara
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Sven Jarius, Friedemann Paul, Orhan Aktaş, Nasrin Asgari, Russell C. Dale, de Sèze, Diego Franciotta, Kazuo Fujihara, A. Jacob, Ho Jin Kim, Ingo Kleiter, Tania Kümpfel, Michael Levy, Jacqueline Palace, Klemens Ruprecht, Albert Saiz, Corinna Trebst, Brian G. Weinshenker, Brigitte Wildemann
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier, Ari Green, Orhan Aktaş, Hans‐Peter Hartung, Fred Lublin, Jörn Drappa, Gerard Barron, Soraya Madani, John N. Ratchford, Dewei She, Daniel Cimbora, Eliezer Katz